# Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease

> **NCT04974099** · PHASE2,PHASE3 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 6 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DEVICE:** RoadMAB precision dashboard
- **DRUG:** Infliximab precision dosing

## Key facts

- **NCT ID:** NCT04974099
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2024-08-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This was the Pilot study. The larger, confirmatory study has started
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04974099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04974099, "Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04974099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*